Skip to main content
. 2022 Dec 27;24(1):442. doi: 10.3390/ijms24010442

Figure 6.

Figure 6

Effects of pre-treatment and co-treatment with VANL-100 compared to parent compounds. Cell viability, represented as % control, is shown on the y-axis, and antioxidant concentrations are displayed on the x-axis. The bars represent the mean ± SEM of six independent experiments. (A,B) Pre-treatment with VANL-100 compared to parent compounds against non-fibril and fibril Aβ25–35, respectively. (C,D) Co-treatment with VANL-100 compared to parent compounds against non-fibril and fibril Aβ25–35, respectively. Statistical significance vs. VANL-100 was assessed using one-way ANOVA. p < 0.05.